• Je něco špatně v tomto záznamu ?

Cystic fibrosis drug trial design in the era of CFTR modulators associated with substantial clinical benefit: stakeholders' consensus view

K. De Boeck, T. Lee, M. Amaral, P. Drevinek, JS. Elborn, I. Fajac, E. Kerem, JC. Davies

. 2020 ; 19 (5) : 688-695. [pub] 20200608

Jazyk angličtina Země Nizozemsko

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc22004856

Grantová podpora
Department of Health - United Kingdom

CFTR modulators associated with substantial clinical benefit are expected to rapidly improve the baseline condition of people with cystic fibrosis (PWCF) as well as decrease the rate of lung function decline, the occurrence of pulmonary exacerbations and likely even other disease complications. These changes in clinical status of PWCF introduced by clinically effective modulator therapy will have major repercussions on modalities of future CF drug development. As part of its 'Strategic Plan to speed up Access to new Drugs', the European Cystic Fibrosis Society (ECFS) convened a meeting in Brussels on November 27th 2019 with relevant stakeholders (CF researchers and clinicians, patient organization and pharmaceutical company representatives, regulators, health technology assessors; see Acknowledgments for list of attendees) to discuss the future of clinical trials in cystic fibrosis (CF) in the context of HEMT entering the clinical arena. The following is the conclusion of the presentations and discussions. It is hoped that these concepts will be considered in future regulatory guidelines and may provide rationale and support for alternative trial designs.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22004856
003      
CZ-PrNML
005      
20220127144917.0
007      
ta
008      
220113s2020 ne f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.jcf.2020.05.012 $2 doi
035    __
$a (PubMed)32527602
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a De Boeck, K $u Department of Paediatrics, University Hospital of Leuven, University of Leuven, Leuven, Belgium. Electronic address: christiane.deboeck@uzleuven.be
245    10
$a Cystic fibrosis drug trial design in the era of CFTR modulators associated with substantial clinical benefit: stakeholders' consensus view / $c K. De Boeck, T. Lee, M. Amaral, P. Drevinek, JS. Elborn, I. Fajac, E. Kerem, JC. Davies
520    9_
$a CFTR modulators associated with substantial clinical benefit are expected to rapidly improve the baseline condition of people with cystic fibrosis (PWCF) as well as decrease the rate of lung function decline, the occurrence of pulmonary exacerbations and likely even other disease complications. These changes in clinical status of PWCF introduced by clinically effective modulator therapy will have major repercussions on modalities of future CF drug development. As part of its 'Strategic Plan to speed up Access to new Drugs', the European Cystic Fibrosis Society (ECFS) convened a meeting in Brussels on November 27th 2019 with relevant stakeholders (CF researchers and clinicians, patient organization and pharmaceutical company representatives, regulators, health technology assessors; see Acknowledgments for list of attendees) to discuss the future of clinical trials in cystic fibrosis (CF) in the context of HEMT entering the clinical arena. The following is the conclusion of the presentations and discussions. It is hoped that these concepts will be considered in future regulatory guidelines and may provide rationale and support for alternative trial designs.
650    _2
$a klinické zkoušky jako téma $x organizace a řízení $7 D002986
650    _2
$a konsensus $7 D032921
650    _2
$a cystická fibróza $x farmakoterapie $x genetika $7 D003550
650    _2
$a protein CFTR $x účinky léků $7 D019005
650    _2
$a vyvíjení léků $x organizace a řízení $7 D000076722
650    _2
$a lidé $7 D006801
650    _2
$a výzkumný projekt $7 D012107
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Lee, T $u Leeds Regional Paediatric Cystic Fibrosis Centre Leeds Children's Hospital, Great George Street Leeds LS1 3EX United Kingdom
700    1_
$a Amaral, M $u University of Lisboa, Faculty of Sciences, BioISI - Biosystems & Integrative Sciences Institute, Campo Grande, C8 bdg, 1749-016 Lisboa, Portugal
700    1_
$a Drevinek, P $u Department of Medical Microbiology, 2nd Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic
700    1_
$a Elborn, J S $u Centre for Experimental Medicine, Queen's University, Belfast, Northern Ireland, United Kingdom
700    1_
$a Fajac, I $u Université Paris Descartes, Sorbonne Paris Cité, Paris, France; AP-HP, Hôpital Cochin, Service de Physiologie et Explorations Fonctionnelles, Paris, France
700    1_
$a Kerem, E $u Department of Paediatrics and CF Center, Hadassah Hebrew University Hospital, Jerusalem Israel
700    1_
$a Davies, J C $u Imperial College London, London, UK. Royal Brompton and Harefield NHS Foundation Trust, London, UK
773    0_
$w MED00006892 $t Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society $x 1873-5010 $g Roč. 19, č. 5 (2020), s. 688-695
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32527602 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220113 $b ABA008
991    __
$a 20220127144914 $b ABA008
999    __
$a ok $b bmc $g 1752151 $s 1156005
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 19 $c 5 $d 688-695 $e 20200608 $i 1873-5010 $m Journal of cystic fibrosis $n J Cyst Fibros $x MED00006892
GRA    __
$p Department of Health $2 United Kingdom
LZP    __
$a Pubmed-20220113

Najít záznam

Citační ukazatele

Možnosti archivace